HLA-A and cancer: CTLs specific to the CMVp495–503–HLA-A*02:01 complex (hereafter referred to as “CMV-pMHCI”) are present in the blood with high prevalence and functional competence among both HLA-A*02:01+ healthy donors and cancer patients [9, 23, 24].